Delivery Order SPE2DB22D3004-SPE2DB25FSD79
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Zepbound 2.5 mg/0.5 mL pen injections (0.5 mL units) with a ceiling value of $1,659.37. This firm fixed-price delivery order, which is set to be completed by August 15, 2025, will be fulfilled from AmerisourceBergen's Conshohocken, Pennsylvania facility. The award represents a non-competitive delivery order issued under AmerisourceBergen's existing indefinite delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Zepbound 5 mg/0.5 ml pens with a ceiling value of $2,726.72. This is a firm fixed-price delivery order with an ultimate completion date of July 30, 2025, and represents a non-set-aside competitive award. The product will be delivered to the company's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,138.12 to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 mL pens on July 31, 2025. This is a firm fixed price delivery order with no set-aside designation, indicating it was competitively awarded. The contract calls for delivery to be completed by August 1, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Zepbound 10 mg/0.5 ml pens in 0.5 ml quantities, valued at $14,093.41. This firm fixed-price delivery order, with an ultimate completion date of August 20, 2025, represents a competitively awarded contract with no set-aside designation. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a $58,304.44 delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Zepbound 10 mg/0.5 mL pens. The contract is a firm fixed-price delivery order with an ultimate completion date of August 4, 2025, and will be performed at the contractor's location in Conshohocken, Pennsylvania. This award carries no set-aside designation and was competitively awarded under an existing contract vehicle. AmerisourceBergen Drug Corp is a major...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 21, 2025, for the supply of Zepbound 5 mg/0.5 ml pens, with a contract value of $6,827.77 and completion deadline of August 22, 2025. This is a firm fixed-price, non-set-aside delivery order classified as a child contract, indicating it was issued under a larger indefinite delivery vehicle. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pens in 0.5 mL quantities, with a ceiling value of $7,625.80. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under the company's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and extending through December 2026. The order is scheduled for...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Zepbound 12.5 mg/0.5 ml pen injections, valued at $6,035.72. This is a firm fixed-price delivery order with no set-aside designation, reflecting a competitively awarded contract. The order is scheduled for completion by August 14, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist...
- The Defense Logistics Agency awarded a delivery order valued at $6,750.31 to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 mL pen injections on August 4, 2025, with an ultimate completion date of August 5, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Zepbound 12.5 mg/0.5 mL pens, a GLP-1 receptor agonist medication used for weight management. This competitively awarded, firm fixed-price delivery order carries a ceiling value of $3,050.40 and an ultimate completion date of August 4, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania....
- SPE2DB22D3004Indefinite Delivery Contract
- SPE2DB22D3004-SPE2DB25FSD79Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Zepbound 2.5 mg/0.5 mL pens with a ceiling value of $10,540.63. This is a firm fixed price delivery order with an ultimate completion date of August 26, 2025, and represents a non-set-aside competitive award. The contract will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive pharmaceutical prime vendor vehicle valued at $999,999,999 through December 2026 that supplies medications and medical supplies to support military healthcare programs globally. AmerisourceBergen Drug Corp is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly for military and veteran healthcare systems. The company's extensive federal contract portfolio with DLA demonstrates its capability to meet competitive procurement requirements for a wide range of pharmaceutical products and medical supplies across multiple therapeutic domains. The delivery of Zepbound, a GLP-1 receptor agonist medication used for weight management, reflects the company's role in supporting military healthcare needs through the DLA Medical Supply Chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $10.5k | 8/25/25 |